Non-steroidal anti-inflammatory drug-induced enteropathy

Sung Jae Shin; Choong-Kyun Noh; Sun Gyo Lim; Kee Myung Lee; Kwang Jae Lee

doi:10.5217/ir.2017.15.4.446

Articles

Page Path: HOME > Intest Res > Volume 15(4); 2017 > Article

Review Non-steroidal anti-inflammatory drug-induced enteropathy: Sung Jae Shin, Choong-Kyun Noh, Sun Gyo Lim, Kee Myung Lee, Kwang Jae Lee; Intestinal Research 2017;15(4):446-455.
DOI: https://doi.org/10.5217/ir.2017.15.4.446
Published online: October 23, 2017

Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.

Correspondence to Sung Jae Shin. Department of Gastroenterology, Ajou University School of Medicine, 164 World cup-ro, Yeongtong-gu, Suwon 16499, Korea. Tel: +82-31-219-5149, Fax: +82-31-219-5999, shsj9128@ajou.ac.kr

• Received: February 16, 2017 • Revised: May 5, 2017 • Accepted: May 7, 2017

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next

17,931 Views
437 Download
47 Web of Science
75 Crossref
80 Scopus

Full Article

Download PDF

Abstract
INTRODUCTION
EPIDEMIOLOGY
PATHOGENESIS
CLINICAL SYMPTOMS AND SIGNS
DIAGNOSIS
PREVENTION AND TREATMENTS
CONCLUSIONS
NOTES
REFERENCES

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are well known to be associated with serious upper gastrointestinal complications, such as peptic ulcer, bleeding, perforation, and obstruction. Recently, attention has been mainly focused on the small bowel injuries caused by NSAIDs, and new endoscopic techniques such as capsule endoscopy and double balloon endoscopy can help in detecting such injuries. This article reviewed the epidemiology, pathogenesis, clinical manifestations, diagnosis, and treatment of small bowel injuries caused by NSAIDs. Small bowel injures by NSAIDs might occur with a similar frequency and extent as those observed in the upper gastrointestinal tract. The pathogenesis of NSAID-induced enteropathy is complex and not clearly understood. The various lesions observed in the small bowel, including petechiae, reddened folds, loss of villi, erosions, and ulcers can be detected by capsule endoscopy. A drug that could prevent or treat NSAID-induced enteropathy has not yet been developed. Therefore, further investigations should be performed to elucidate the pathogenesis of such enteropathy and develop suitable preventive and treatment strategies.
Keywords: Anti-inflammatory agents, non-steroidal; Small intestine injury; Capsule endoscopy

INTRODUCTION

Non-steroidal anti-inflammatory drugs (NSAIDs) are some of the most commonly prescribed drugs in the world. As a result of their anti-inflammatory, analgesic, and anti-platelet effects, NSAIDs are used in clinical practice for treatment and prevention of rheumatoid arthritis, osteoarthritis, collagen disease, and ischemic cardiovascular or cerebrovascular disease. However, NSAIDs are well known to increase the risk of serious gastroduodenal complications, such as peptic ulcer, bleeding, and perforations.1 2

Until recently, many studies regarding NSAID-induced gastrointestinal (GI) injuries were focused on the stomach and duodenum because of easy accessibility via upper endoscopy. However, recent advances in diagnostic devices used to look at the small intestine, such as capsule endoscopy (CE) and double balloon endoscopy (DBE), enabled direct visualization of the small bowel, and revealed the small bowel injuries induced by NSAIDs.3 4 5 6 7 Graham et al.3 reported that small bowel damage was found in 71% of chronic NSAID users. However, unlike the NSAID-induced gastropathy, the symptoms of NSAID-induced enteropathy are non-specific and the pathogenesis is poorly understood. Additionally, there is no proven effective treatment or prevention for NSAID-induced enteropathy.

Therefore, studies to investigate the mechanism of NSAID-induced enteropathy and treatment modalities for small bowel damage should be performed in the future. In this paper, we intend to describe the current status of small bowel injuries caused by NSAIDs.

EPIDEMIOLOGY

Over the last 10 years, there has been a progressive trend in overall GI complications, such as bleeding and perforation, with a decrease in upper GI complications and an increase in lower GI complications, which include the jejunum, ileum, and large bowel. Thus, the ratio of upper to lower complications has changed from 4.1 in 1996 to 1.4 in 2005.8

Among NSAID users, a 15% prevalence of gastric ulcer and a 10% prevalence of duodenal ulcer was found in an endoscopic study.9 There are several reasons that make it difficult to recognize the prevalence of NSAID-induced enteropathy. First, observing small bowel injuries, induced by NSAIDs, is more difficult than those in the upper GI tract. Second, there is a poor correlation between NSAID-induced small intestinal damage and clinical symptoms. Most symptoms caused by NSAID-induced enteropathy are subclinical and non-specific.10 11 Therefore, until the introduction of CE and DBE, the importance of NSAID-induced enteropathy had been underestimated, compared with NSAID-induced gastropathy.

Recent studies suggested that the damage to the small bowel may occur as frequently and be as severe as upper GI complications.10 11 Allison et al.12 reported the prevalence of small intestinal injuries (ulcerations) in NSAID users and non-users in post mortem patients. Small intestinal ulceration was found in 8.4% of the NSAID users and 0.6% of the non-users. In a study looking at results of capsule enteroscopies, Maiden et al.4 found that small bowel injuries were observed in 68% of healthy volunteers taking diclofenac plus omeprazole for 2 weeks. In another study with 28 rheumatoid arthritis patients, small bowel damage was detected in 13 of 16 patients (81.3%) who used NSAIDs and in 4 of 12 patients (33.3%) who did not.5 In the study using DBE, the NSAID enteropathy occurred in 51% of the patients taking NSAIDs.13 Aspirin seemed to be less harmful to the small bowel in comparison with other NSAIDs.14 15 16 However, even low-dose aspirin can cause bowel damage with short-term administration. Endo et al.14 reported that small bowel injuries occurred more frequently in healthy volunteers to whom low-dose enteric-coated aspirin was administered for 14 days, than in the group not given any drug (80% vs. 20%, P=0.023). Therefore, considering these results, it is necessary to be aware of the adverse effect of NSAIDs not only on the upper GI tract but also the lower GI tract.

PATHOGENESIS

Unlike that of the upper GI tract, the pathogenesis of small bowel injuries caused by NSAIDs was not clearly elucidated in the past because various multiple complicating factors were thought to influence the development of NSAID-induced enteropathy.

Bjarnason et al.17 suggested a 3-hit hypothesis. First, the phospholipid in the cell membrane on the mucosal surface is directly damaged by NSAIDs and subsequently, injury of the mitochondria in the cell occurs. Second, mitochondrial damage induces the decrease of energy synthesis, resulting in calcium efflux and generation of free radicals. Then, disruption of intercellular junctions and increase of mucosal permeability develop. Third, the intraluminal contents, such as bile acid, proteolytic enzymes, intestinal bacteria, and toxins, can invade the cell through the weakened mucosal barrier, and inflammation develops (Fig. 1).18

PGs have an important role in GI blood flow and mucus production. The depletion of PGs by NSAIDs induces small bowel damage.19 20 21 22 There are 2 type of cyclooxygenase (COX). COX-1 induces PG synthesis and has an important role in maintaining the homeostasis of intestinal mucosa. Previously, only COX-1 inhibition was thought to be associated with mucosal injuries. However, in a recent animal model study, small intestinal damage developed only when both COX-1 and COX-2 were inhibited.23 This indicates that COX-2-derived PGs also play an important role in maintenance of the integrity of the tissue, repairing of mucosal injury, and resolution of inflammation. One study reported that the small bowel injuries by non-selective NSAIDs and selective COX-2 inhibitors were not significantly different in patients on long-term NSAIDs (62% with conventional NSAIDs vs. 50% with selective COX-2 inhibitors, P-value not significant).6

Enterohepatic circulation of NSAIDs also has an important role in the pathogenesis of NSAID-induced enteropathy.24 25 26 The topical adverse effect of aspirin was thought to be localized in the gastroduodenum because of rapid absorption in the stomach and duodenum and the lack of enterohepatic recirculation. To reduce gastric mucosal injuries caused by the topical irritant effect of aspirin, enteric-coated aspirin has been developed.27 28 29 30 Enteric-coated aspirin dissolves mainly in the small bowel, rather than the stomach or duodenum, and enters the enterohepatic circulation, which damages mostly the distal part of the small intestine. When NSAIDs or aspirin did not re-circulate enterohepatically, NSAID-induced small bowel injuries could not develop.31 32 One study reported that small bowel ulcers occurred more frequently in patients taking enteric-coated aspirin (56.3%) than non-coated aspirin (16.7%).14

Intestinal bacteria are important in the pathogenesis of NSAID-induced enteropathy. Germ-free rats and mice had little or no intestinal injuries when given NSAIDs, but when the bowel was colonized by gram-negative bacteria, the small intestine was susceptible to injuries caused by NSAIDs.19 33 In addition, some antibiotics, which work against gram-negative bacteria, were effective in reducing NSAID-induced enteropathy.33 34 35 The lipopolysaccharide of gram-negative bacteria activated the Toll-like receptor 4, which stimulated an inflammatory response, such as cytokine activation and tumor necrosis factor α, triggering nitric oxide (NO) derived from inducible NO synthase and neutrophil activation, resulting in small bowel mucosal injuries.34 35 36 37 38 39 The NSAIDs, acryl glucuronides, which are excreted from the hepatocytes into the bile duct, are deconjugated by an intestinal bacterial enzyme, β-glucuronidase. Subse-quently, NSAIDs could be transported across the epithelium and enter the enterohepatic circulation. The inhibition of β-glucuronidase in an animal model reduced the diclofenac-induced small bowel injuries.40 The low acidity of the gastric environment suppresses bacteria; therefore, chronic acid suppression by proton pump inhibitors (PPIs) can induce bacterial overgrowth and exacerbate the NSAID-induced enteropathy through dysbiosis.41 42 43 44 Similarly, probiotics could decrease the severity of NSAID-induced enteropathy.45

CLINICAL SYMPTOMS AND SIGNS

The signs and symptoms of NSAID-induced enteropathy are usually nonspecific. They have various manifestations, such as iron-deficiency anemia, protein loss, indigestion, constipation, diarrhea, and abdominal pain.10 11 Serious clinical complications, i.e., bleeding, obstruction, and perforation, are infrequent, but can be life threatening.

NSAID-induced enteropathy is associated with occult or overt GI bleeding, resulting in iron-deficiency anemia. In CE, ulcerations and erosions are found commonly in patients taking NSAIDs.4 5 6 7 Kameda et al.46 reported that NSAID-induced enteropathy was the most common etiology of obscure GI bleeding.

Protein losing enteropathy is another clinical manifestation of NSAID-induced enteropathy, which can lead to hypoalbuminemia. Low serum albumin was detected in 10% of rheumatoid arthritis patients taking NSAIDs.47 In a study using ⁵¹chromium, the protein loss was observed mainly at the distal ileum level in long-term NSAID users.48

Diaphragm-like stricture is a rare, but pathognomonic, feature of NSAID-induced enteropathy. The numerous concentric, luminal projections of fibrotic submucosal tissue may cause non-specific or obstructive symptoms.49 50 However, because of the intact proper muscle layers, perforation was uncommon. Recently, balloon dilation, instead of surgery, was successfully performed to relieve obstructive symptoms.50 In other studies, NSAID-induced enteropathy was reported to be associated with diverticulitis and diverticular bleeding, vitamin B₁₂ deficiency, and the impairment of bile acid absorption.47 51 52

DIAGNOSIS

The most important reason for underestimating the clinical importance of NSAID-induced enteropathy is the difficulty in making a diagnosis. Before introduction of CE and DBE, the diagnosis of NSAID-induced enteropathy relied on the measurement of small bowel permeability and inflammation. To assay the small bowel permeability, orally administered materials should be shown to be rarely absorbed by an intact small bowel barrier, and absorption should occur only in an area of a damaged intestinal barrier. Then, the absorbed materials are excreted in the urine. Therefore, the severity of small bowel injuries could be confirmed through the amount of the excreted materials in the urine. The permeability of chromium-51-labeled EDTA (⁵¹Cr-EDTA) was relatively specific to the small intestine and it was the most widely used in measuring NSAID-induced enteropathy.48 53 54 One study using ⁵¹Cr-EDTA permeability showed that the small bowel was more damaged as the dose of NSAIDs was increased (19% with 750 mg naproxen vs. 68% with 1,000 mg naproxen).48 The inflammation of the small intestine could also be detected in scintigraphy using ¹¹¹indium (In)-labeled leukocytes. The 50% to 70% of patients taking long-term NSAIDs showed enhanced uptake in the small bowel,55 but this test was difficult to use in clinical practice because of its high cost.

Calprotectin, which is a protein in the cytosol of neutrophils, monocytes, and macrophages, can be used as an inflammatory marker of the small intestine. By checking the amount of fecal calprotectin, small bowel injuries caused by NSAIDs could be estimated. One study showed that the level of a single fecal calprotectin was correlated with the 4-day fecal excretion of ¹¹¹In-labeled leukocytes.53 However, fecal calprotectin had low specificity because it could be elevated in IBD, colon cancer, and other inflammatory conditions.

CE and DBE enabled the direct visualization of the small intestine and more exact localization of small bowel injuries. Therefore, the small bowel injuries, caused by NSAIDs, could be better understood using these diagnostic modalities. Compared with DBE, CE is a painless procedure, and has been used easily to evaluate the small bowel injuries caused by NSAIDs. Hayashi et al.56 defined the criteria of NSAID-induced enteropathy as (1) history of NSAID use; (2) endoscopic findings, such as erosions, ulcers, and diaphragm-like strictures; (3) improvement of clinical manifestations and/or endoscopic findings after stopping the NSAIDs; and (4) exclusion of other etiologies, such as IBD, infection, and malignancy. Various findings such as erosions, ulcers, and strictures were found by CE (Fig. 2). Maiden et al.4 divided the NSAID injuries found by CE into 5 categories: petechiae (demarcated areas of crimson mucosa), reddened folds, denuded areas (loss of villi), mucosal breaks (mucosal erosions and/or ulcers), and presence of blood without a visualized lesion.20 In this report, mucosal breaks were detected in about 40% of healthy volunteers after taking 150 mg/day of diclofenac for 2 weeks. In a DBE study, multiple discrete ulcers were found in 28% of patients taking NSAIDs.13 Graham et al.3 reported that mucosal lesions, including red spots, small erosions, large erosions, and ulcers, developed in 13 out of 21 patients (62%) who were chronic NSAID users. As the ability to find small lesions using CE and DBE was not comprehensive, further advanced modalities should be developed.

PREVENTION AND TREATMENTS

The most effective method of preventing NSAID-induced enteropathy is to discontinue the NSAIDs. However, even if temporary withdrawal of NSAIDs is possible, it would be medically contraindicated to stop the NSAIDs continuously in patients with chronic pain or anti-platelet therapy. Therefore, prophylactic drugs are essential in chronic NSAID users, especially if there is suspected small bowel bleeding. Until recently, although many efforts have been attempted, there were no methods or medications to prevent or cure NSAID-induced enteropathy. Medications, such as H₂ antagonists, sucralfate, or PPIs, which were developed to minimize upper GI injuries caused by NSAIDs, did not prevent the small intestine injuries.10 11

COX-2 inhibitors produced less gastroduodenal ulceration and bleeding, compared with non-selective NSAIDs. Therefore, COX-2 inhibitors were thought to be less toxigenic to the small bowel.57 58 Goldstein et al.5 showed that small bowel injuries were lower in patients taking celecoxib for 2 weeks, compared with naproxen combined with omeprazole. COX-2 was thought to be associated with maintenance of the integrity of the tissue, repair of mucosal injury, and resolution of inflammation.59 60 However, in patients taking COX-2 inhibitors for more than 3 months, there was no significant difference in the incidence of small bowel injuries between the users of selective COX-2 inhibitors and conventional NSAID users.6 61 Further studies should be performed to determine whether the COX-2 inhibitors can reduce small bowel toxicities.

PG has an important role in mucosal protection; misoprostol, a synthetic PG analog, demonstrated a decrease in the intestinal permeability caused by NSAIDs in several studies.62 63 Watanabe et al.64 reported that misoprostol, but not PPI therapy, was effective in improving mucosal injuries using CE in patients who had developed gastric ulcers when taking low-dose aspirin. Conversely, there was no reduction of the intestinal permeability of ⁵¹Cr-EDTA in patients taking indomethacin, even when low dose of misoprostol was given.47 Despite the effectiveness in treating NSAID-induced enteropathy, misoprostol causes many GI adverse effects, such as nausea, indigestion, abdominal pain, and diarrhea.65 These side effects could limit its clinical use.

Rebamipide is a drug that promotes GI mucosal protection by increasing mucus and stimulating PG synthesis.66 67 It also scavenges free radicals and suppresses myeloperoxidase activity. In a study using CE, Niwa et al.68 showed its effectiveness in treating NSAID-induced enteropathy in healthy humans. Small intestine injuries were less frequent in the patients receiving diclofenac for 7 days, together with rebamipide, than in those receiving a placebo (20% with rebamipide vs. 80% with placebo). However, in the larger study, there was no difference between the group taking diclofenac, PPI, and rebamipide for 14 days and the group taking diclofenac, PPI, and a placebo.69 Furthermore, additional studies should be performed to clarify the effectiveness of rebamipide in treating NSAID-induced enteropathy.

Metronidazole is an antibiotic, which is effective against many enteric anaerobic bacteria. Bjarnason et al.70 reported that co-administered metronidazole (with NSAIDs) was effective in reducing NSAID-induced enteropathy. The patients taking NSAIDs received metronidazole and the fecal excretion of ⁵¹Cr-labeled erythrocytes and ¹¹¹In-labeled neutrophils was measured. These 2 fecal inflammatory markers were reduced with the treatment of metronidazole. Recently, several studies have evaluated the potential value of probiotics for prevention or treatment of NSAID-induced enteropathy.45 71 72 In animal models, Lactobacillus acidophilus and Bifidobacterium adolescentis reduced ileal ulcer formation in rats treated with NSAIDs.70 In a clinical trial, CE showed a significant reduction of mucosal breaks in the Lactobacillus casei group compared with the placebo group in patients receiving low-dose enteric-coated aspirin and omeprazole treatment for more than 3 months.45 Additionally, VSL#3, a probiotic formulation consisting of 8 different species of microorganisms, was effective in reducing the fecal calprotectin level in volunteers taking indomethacin.72

PPIs strongly inhibit gastric acid secretion and are prescribed for prevention and treatment of gastroduodenal ulcers by NSAIDs. A previous study found that lansoprazole was effective in reducing small bowel injuries caused by NSAIDs in animal models.73 The mechanism of preventing small bowel injuries by lansoprazole was thought to be by inducing the heme oxygenase-1, which has an important role in inhibiting NSAID-induced small bowel injuries.73 74 Pretreatment with tin-protoporphyrin, which is an inhibitor of heme oxygenase-1, increased the indomethacin-induced enteropathy. On the contrary, lansoprazole exacerbated the small bowel injuries in rats treated with naproxen.75 In a clinical study using CE, small bowel injuries were found more commonly in patients treated with naproxen and omeprazole (55%) than those treated with other medications (16% with celecoxib only, 7% in controls).5 The aggravation of NSAID-induced small bowel injuries by PPIs could be explained by their potential to cause a shift in the types of bacteria in the small intestine (dysbiosis).44 The rats treated with omeprazole had a significant reduction in Actinobacteria, particularly Bifidobacteria, in the jejunum; however, the addition of Bifidobacteria in PPI-treated rats reduced the NSAID-induced intestinal damage.44 For lansoprazole, a clinical trial will be needed to confirm the effect, considering the 2 conflicting reports.

Several drugs, such as NO-releasing NSAIDs and hydrogen sulfide (H₂S)-releasing NSAIDs have been developed using the co-drug model. The NO or H₂S portions of the co-drugs promote mucosal protection via increasing mucosal blood flow and inhibiting leukocyte adherence to the endothelium. In a clinical trial, NO-naproxen decreased small bowel permeability compared with an equivalent dose of naproxen.75 Additionally, H₂S-releasing NSAIDs showed enhanced anti-inflammatory activity in comparison to the conventional NSAIDs.76 77 78

Phospholipid has been proposed to reduce the topical irritant property of NSAIDs.79 80 81 In those studies, it was a component of the epithelial barrier to acid-back diffusion and had an important role in preventing the NSAIDs from disrupting the barrier. The phospholipid lining of the mucosal surface, which was hydrophobic, suppressed the invasion of acid, bile, and other toxic materials. In an animal study, small bowel injuries were not found in the phosphatidylcholine (PC)-indomethacin group.82 In clinical trials, PC-ibuprofen reduced the gastroduodenal injuries, as compared to ibuprofen.83 However, there are no clinical studies regarding the effectiveness of PC-NSAIDs in small bowel injuries.

Sulfasalazine may be a possible treatment modality in NSAID-induced enteropathy. In rheumatoid arthritis patients taking NSAIDs, sulfasalazine reduced intestinal inflammation and blood loss, whereas disease-modifying anti-rheumatic drugs did not.84

CONCLUSIONS

NSAID-induced enteropathy may be as frequent and severe as upper GI complications. In most cases, clinical manifestations are non-specific and pathogenic mechanisms are not well known, but are suspected to be complicated. The new diagnostic modalities, such as CE and DBE, enable diagnosis of small bowel injuries caused by NSAIDs more easily than in the past. However, there is no proven effective medication for treating NSAID-induced enteropathy. Therefore, further studies regarding the prevention and treatment of intestinal injuries caused by NSAIDs are urgently needed.

NOTES

Financial support: None.

Conflict of interest: None.

REFERENCES

1. Fries JF, Williams CA, Bloch DA, Michel BA. Non-steroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991;91:213–222.PMID: 1892140.Article PubMed
2. Smalley WE, Ray WA, Daugherty JR, Griffin MR. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995;141:539–545.PMID: 7900721.Article PubMed PDF
3. Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 2005;3:55–59.PMID: 15645405.Article PubMed
4. Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005;128:1172–1178.PMID: 15887101.Article PubMed
5. Goldstein JL, Eisen GM, Lewis B, et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005;3:133–141.PMID: 15704047.Article PubMed
6. Maiden L, Thjodleifsson B, Seigal A, et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol 2007;5:1040–1045.PMID: 17625980.Article PubMed
7. Maiden L. Capsule endoscopic diagnosis of nonsteroidal antiinflammatory drug-induced enteropathy. J Gastroenterol 2009;44(Suppl 19): 64–71.PMID: 19148796.Article PubMed
8. Lanas A, García-Rodríguez LA, Polo-Tomás M, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol 2009;104:1633–1641.PMID: 19574968.Article PubMed PDF
9. Hudson N, Hawkey CJ. Non-steroidal anti-inflammatory drug-associated upper gastrointestinal ulceration and complications. Eur J Gastroenterol Hepatol 1993;5:412–419.Article
10. Park SC, Chun HJ, Kang CD, Sul D. Prevention and management of non-steroidal anti-inflammatory drugs-induced small intestinal injury. World J Gastroenterol 2011;17:4647–4653.PMID: 22180706.Article PubMed PMC
11. Lim YJ, Yang CH. Non-steroidal anti-inflammatory drug-induced enteropathy. Clin Endosc 2012;45:138–144.PMID: 22866254.Article PubMed PMC
12. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl J Med 1992;327:749–754.PMID: 1501650.Article PubMed
13. Matsumoto T, Kudo T, Esaki M, et al. Prevalence of non-steroidal anti-inflammatory drug-induced enteropathy determined by double-balloon endoscopy: a Japanese multicenter study. Scand J Gastroenterol 2008;43:490–496.PMID: 18365915.Article PubMed
14. Endo H, Hosono K, Inamori M, et al. Characteristics of small bowel injury in symptomatic chronic low-dose aspirin users: the experience of two medical centers in capsule endoscopy. J Gastroenterol 2009;44:544–549.PMID: 19373431.Article PubMed
15. Leung WK, Bjarnason I, Wong VW, Sung JJ, Chan FK. Small bowel enteropathy associated with chronic low-dose aspirin therapy. Lancet 2007;369:614PMID: 17307109.Article PubMed
16. Stattery J, Warlow CP, Shorrock CJ, Langman MJ. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin: analysis of gastrointestinal bleeding during the UK-TIA trial. Gut 1995;37:509–511.PMID: 7489937.Article PubMed PMC
17. Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993;104:1832–1847.PMID: 8500743.Article PubMed
18. Wallace JL. NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies. Br J Pharmacol 2012;165:67–74.PMID: 21627632.Article PubMed PMC
19. Robert A, Asano T. Resistance of germ-free rats to indomethacin induced intestinal inflammation. Prostaglandins 1977;14:333–341.PMID: 331401.Article PubMed
20. Fang WF, Broughton A, Jacobson ED. Indomethacin induced intestinal inflammation. Am J Dig Dis 1977;22:749–760.PMID: 900091.Article PubMed
21. Whittle BJ. Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology 1981;80:94–98.PMID: 6778761.Article PubMed
22. Yamada T, Deitch E, Specian RD, Perry MA, Sartor RB, Grisham MB. Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation 1993;17:641–662.PMID: 7906675.Article PubMed
23. Sigthorsson G, Simpson RJ, Walley M, et al. COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology 2002;122:1913–1923.PMID: 12055598.Article PubMed
24. Wax J, Clinger WA, Varner P, Bass P, Winder CV. Relationship of the enterohepatic cycle to ulcerogenesis in the rat small bowel with flufenamic acid. Gastroenterology 1970;58:772–780.PMID: 5423889.Article PubMed
25. Jacob M, Foster R, Sigthorsson G, Simpson R, Bjarnason I. Role of bile in pathogenesis of indomethacin-induced enteropathy. Arch Toxicol 2007;81:291–298.PMID: 17151867.Article PubMed
26. Lichtenberger LM, Phan T, Okabe S. Aspirin's ability to induce intestinal injury in rats is dependent on bile and can be reversed if pre-associated with phosphatidylcholine. J Physiol Pharmacol 2011;62:491–496.PMID: 22100851.PubMed
27. Dammann HG, Burkhardt F, Wolf N. Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions. Aliment Pharmacol Ther 1999;13:1109–1114.PMID: 10468689.Article PubMed
28. Blondon H, Barbier JP, Mahé I, Deverly A, Kolsky H, Bergmann JF. Gastroduodenal tolerability of medium dose enteric-coated aspirin: a placebo controlled endoscopic study of a new enteric coated formation versus regular formation in healthy volunteers. Fundam Clin Pharmacol 2000;14:155–157.PMID: 10796063.Article PubMed
29. Lanza FL, Royer GL Jr, Nelson RS. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med 1980;303:136–138.PMID: 6966762.Article PubMed
30. Petroski D. Endoscopic comparison of three aspirin preparations and placebo. Clin Ther 1993;15:314–320.PMID: 8519040.PubMed
31. Reuter BK, Davies NM, Wallace JL. Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 1997;112:109–117.PMID: 8978349.Article PubMed
32. Somasundaram S, Rafi S, Hayllar J, et al. Mitochondrial damage: a possible mechanism of the “topical” phase of NSAID induced injury to the rat intestine. Gut 1997;41:344–353.PMID: 9378390.Article PubMed PMC
33. Uejima M, Kinouchi T, Kataoka K, Hiraoka I, Ohnishi Y. Role of intestinal bacteria in ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug. Microbiol Immunol 1996;40:553–560.PMID: 8887349.Article PubMed
34. Watanabe T, Higuchi K, Kobata A, et al. Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll like receptor 4 dependent. Gut 2008;57:181–187.PMID: 17639086.Article PubMed
35. Koga H, Aoyagi K, Matsumoto T, Iida M, Fujishima M. Experimental enteropathy in athymic and euthymic rats: synergistic role of lipopolysaccharide and indomethacin. Am J Physiol 1999;276(3 Pt 1): G576–G582.PMID: 10070032.Article PubMed
36. Whittle BJ. Nitric oxide and the gut injury induced by non-steroidal anti-inflammatory drugs. Inflammopharmacology 2003;11:415–422.PMID: 15035794.Article PubMed
37. Santucci L, Fiorucci S, Di Matteo FM, Morelli A. Role of tumor necrosis factor alpha release and leukocyte margination in indomethacin-induced gastric injury in rats. Gastroenterology 1995;108:393–401.PMID: 7530670.Article PubMed
38. Reuter BK, Wallace JL. Phosphodiesterase inhibitors prevent NSAID enteropathy independently of effects on TNF alpha release. Am J Physiol 1999;277(4 Pt 1): G847–G854.PMID: 10516151.PubMed
39. Bertrand V, Guimbaud R, Tulliez M, et al. Increase in tumor necrosis factor-alpha production linked to the toxicity of indomethacin for the rat small intestine. Br J Pharmacol 1998;124:1385–1394.PMID: 9723949.Article PubMed PMC
40. LoGuidice A, Wallace BD, Bendel L, Redinbo MR, Boelsterli UA. Pharmacologic targeting of bacterial beta-glucuronidase alleviates nonsteroidal anti-inflammatory drug-induced enteropathy in mice. J Pharmacol Exp Ther 2012;341:447–454.PMID: 22328575.Article PubMed PMC
41. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010;8:504–508.PMID: 20060064.Article PubMed
42. Compare D, Pica L, Rocco A, et al. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest 2011;41:380–386.PMID: 21128930.Article PubMed
43. Jacobs C, Coss Adame E, Attaluri A, Valestin J, Rao SS. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Aliment Pharmacol Ther 2013;37:1103–1111.PMID: 23574267.Article PubMed PMC
44. Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011;141:1314–1322.PMID: 21745447.Article PubMed
45. Endo H, Higurashi T, Hosono K, et al. Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. J Gastroenterol 2011;46:894–905.PMID: 21556830.Article PubMed
46. Kameda N, Higuchi K, Shiba M, et al. A prospective, single-blind trial comparing wireless capsule endoscopy and double-balloon enteroscopy in patients with obscure gastrointestinal bleeding. J Gastroenterol 2008;43:434–440.PMID: 18600387.Article PubMed
47. Davies NM, Saleh JY, Skjodt NM. Detection and prevention of NSAID-induced enteropathy. J Pharm Pharm Sci 2000;3:137–155.PMID: 10954683.PubMed
48. Aabakken L, Osnes M. 51Cr-ethylenediaminetetraacetic acid absorption test: effects of naproxen, a non-steroidal, anti-inflammatory drug. Scand J Gastroenterol 1990;25:917–924.PMID: 2120769.Article PubMed
49. Santolaria S, Cabezali R, Ortego J, et al. Diaphragm disease of the small bowel: a case without apparent nonsteroidal antiinflammatory drug use. J Clin Gastroenterol 2001;32:344–346.PMID: 11276281.Article PubMed
50. Sunada K, Yamamoto H. Double-balloon endoscopy: past, present, and future. J Gastroenterol 2009;44:1–12.Article PMC
51. Rahme E, Barkun A, Nedjar H, Gaugris S, Watson D. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada. Am J Gastroenterol 2008;103:872–882.PMID: 18371130.Article PubMed
52. Zuccaro G. Epidemiology of lower gastrointestinal bleeding. Best Pract Res Clin Gastroenterol 2008;22:225–232.PMID: 18346680.Article PubMed
53. Lanas A, Sopeña F. Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications. Gastroenterol Clin North Am 2009;38:333–352.PMID: 19446262.Article PubMed
54. Davies GR, Rampton DS. The pro-drug sulindac may reduce the risk of intestinal damage associated with the use of conventional non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 1991;5:593–598.PMID: 1782303.Article PubMed
55. Davies NM. Sustained release and enteric coated NSAIDs: are they really GI safe? J Pharm Pharm Sci 1999;2:5–14.PMID: 10951657.PubMed
56. Hayashi Y, Yamamoto H, Kita H, et al. Non-steroidal anti-inflammatory drug-induced small bowel injuries identified by double-balloon endoscopy. World J Gastroenterol 2005;11:4861–4864.PMID: 16097059.Article PubMed PMC
57. Smecuol E, Bai JC, Sugai E, et al. Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs. Gut 2001;49:650–655.PMID: 11600467.Article PubMed PMC
58. Takeuchi K, Tanaka A, Kato S, Amagase K, Satoh H. Roles of COX inhibition in pathogenesis of NSAID-induced small intestinal damage. Clin Chim Acta 2010;411:459–466.PMID: 20074562.Article PubMed
59. Wallace JL, Devchand PR. Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense. Br J Pharmacol 2005;145:275–282.PMID: 15778736.Article PubMed PMC
60. Sugimori S, Watanabe T, Tabuchi M, et al. Evaluation of small bowel injury in patients with rheumatoid arthritis by capsule endoscopy: effects of anti-rheumatoid arthritis drugs. Digestion 2008;78:208–213.PMID: 19142000.Article PubMed
61. Laine L, Curtis SP, Langman M, et al. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology 2008;135:1517–1525.PMID: 18823986.Article PubMed
62. Fujimori S, Seo T, Gudis K, et al. Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointest Endosc 2009;69:1339–1346.PMID: 19243767.Article PubMed
63. Fujimori S, Takahashi Y, Seo T, et al. Prevention of traditional NSAID-induced small intestinal injury: recent preliminary studies using capsule endoscopy. Digestion 2010;82:167–172.PMID: 20588029.Article PubMed
64. Watanabe T, Sugimori S, Kameda N, et al. Small bowel injury by low dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol 2008;6:1279–1282.PMID: 18995219.Article PubMed
65. Fortun PJ, Hawkey CJ. Nonsteroidal antiinflammatory drugs and the small intestine. Curr Opin Gastroenterol 2007;23:134–141.PMID: 17268241.Article PubMed
66. Arakawa T, Watanabe T, Fukuda T, Yamasaki K, Kobayashi K. Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer: comparison with cimetidine. Dig Dis Sci 1995;40:2469–2472.PMID: 7587834.Article PubMed
67. Higuchi K, Umegaki E, Watanabe T, et al. Present status and strategy of NSAIDs-induced small bowel injury. J Gastroenterol 2009;44:879–888.PMID: 19568687.Article PubMed
68. Niwa Y, Nakamura M, Ohmiya N, et al. Efficacy of rebamipide for diclofenac induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo controlled, cross-over study. J Gastroenterol 2008;43:270–276.PMID: 18458842.Article PubMed
69. Fujimori S, Takahashi Y, Gudis K, et al. Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a double blind, randomized, controlled trial evaluated by capsule endoscopy. J Gastroenterol 2011;46:57–64.PMID: 20924615.Article PubMed
70. Bjarnason I, Hayllar J, Smethurst P, Price A, Gumpel MJ. Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy. Gut 1992;33:1204–1208.PMID: 1427372.Article PubMed PMC
71. Kinouchi T, Kataoka K, Bing SR, et al. Culture supernatants of Lactobacillus acidophilus and Bifidobacterium adolescentis repress ileal ulcer formation in rats treated with a nonsteroidal anti-inflammatory drug by suppressing unbalanced growth of aerobic bacteria and lipid peroxidation. Microbiol Immunol 1998;42:347–355.PMID: 9654366.Article PubMed
72. Montalto M, Gallo A, Curigliano V, et al. Clinical trial: the effects of a probiotic mixture on non-steroidal anti-inflammatory drug enteropathy: a randomized, double blind, cross-over, placebo-controlled study. Aliment Pharmacol Ther 2010;32:209–214.PMID: 20384610.Article PubMed
73. Yoda Y, Amagase K, Kato S, et al. Prevention by lansoprazole, a proton pump inhibitor, of indomethacin-induced small intestinal ulceration in rats through induction of heme oxygenase-1. J Physiol Pharmacol 2010;61:287–294.PMID: 20610858.PubMed
74. Higuchi K, Yoda Y, Amagase K, et al. Prevention of NSAID-induced small bowel intestinal mucosal injury: prophylactic potential of lansoprazole. J Clin Biochem Nutr 2009;45:125–130.PMID: 19794918.Article PubMed PMC
75. Hawkey CJ, Jones JI, Atherton CT, et al. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut 2003;52:1537–1542.PMID: 14570719.Article PubMed PMC
76. Sparatore A, Perrino E, Tazzari V, et al. Pharmacological profile of a novel H(2)S-releasing aspirin. Free Radic Biol Med 2009;46:586–592.PMID: 19100325.Article PubMed
77. Wallace JL, Vong L, McKnight W, Dicay M, Martin GR. Endogenous and exogenous hydrogen sulfide promotes resolution of colitis in rats. Gastroenterology 2009;137:569–578.PMID: 19375422.Article PubMed
78. Wallace JL, Ferraz JG, Muscara MN. Hydrogen sulfide: an endogenous mediator of resolution of inflammation and injury. Antioxid Redox Signal 2012;17:58–67.PMID: 22017247.Article PubMed PMC
79. Lichtenberger LM, Wang ZM, Romero JJ, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat Med 1995;1:154–158.PMID: 7585013.Article PubMed PDF
80. Lichtenberger LM, Zhou Y, Dial EJ, Raphael RM. NSAID injury to the gastrointestinal tract: evidence that NSAIDs interact with phospholipids to weaken the hydrophobic surface barrier and induce the formation of unstable pores in membranes. J Pharm Pharmacol 2006;58:1421–1428.PMID: 17132203.Article PubMed
81. Lichtenberger LM, Barron M, Marathi U. Association of phosphatidylcholine and NSAIDs as a novel strategy to reduce gastrointestinal toxicity. Drugs Today (Barc) 2009;45:877–890.PMID: 20135022.Article PubMed
82. Lim YJ, Phan TM, Dial EJ, Graham DY, Lichtenberger LM. In vitro and in vivo protection against indomethacin induced small intestinal injury by proton pump inhibitors, acid pump antagonists, or indomethacin-phosphatidylcholine. Digestion 2012;86:171–177.PMID: 22907267.Article PubMed PMC
83. Lanza FL, Marathi UK, Anand BS, Lichtenberger LM. Clinical trial: comparison of ibuprofen-phosphatidylcholine and ibuprofen on the gastrointestinal safety and analgesic efficacy in osteoarthritic patients. Aliment Pharmacol Ther 2008;28:431–442.PMID: 18549459.Article PubMed PMC
84. Hayllar J, Smith T, Macpherson A, Price AB, Gumpel M, Bjarnason I. Nonsteroidal anti-inflammatory drug-induced small intestinal inflammation and blood loss: effects of sulfasalazine and other disease-modifying antirheumatic drugs. Arthritis Rheum 1994;37:1146–1150.PMID: 7914409.Article PubMed

Fig. 1

Putative pathophysiology of NSAID-induced enteropathy. NSAIDs decrease PG synthesis, resulting in the reduction of mucus and blood flow of the intestinal mucosa and directly damage the small bowel epithelium. These injuries cause increased intestinal permeability of bile acid, bacteria, proteolytic enzymes, and toxins. Therefore, neutrophils and many inflammatory mediators are activated and various clinical manifestations, such as erosion, ulceration, bleeding, and protein loss develop. Additionally, enterohepatic circulation of NSAIDs and bile augments the damage to the small bowel. TLR4, Toll-like receptor 4. Adapted from Wallace JL. Br J Pharmacol 2012;165:67-74.18

Fig. 2

Capsule endoscopic images of various intestinal mucosal lesions by NSAID. (A) Small bowel petechiae, (B) small bowel erosion, (C) small bowel ulcer, (D) small bowel ulcer with adherent blood clots, (E) small bowel active bleeding, and (F) small bowel stricture with adherent clots.

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Risk of Lower Gastrointestinal Bleeding in Nonsteroidal Anti-inflammatory Drug (NSAID) and Proton Pump Inhibitor Users Compared with NSAID-Only Users: A Common Data Model Analysis
Moonhyung Lee, Myoungsuk Kim, Jae Myung Cha
Gut and Liver.2025; 19(2): 243. CrossRef
Celecoxib is the only nonsteroidal anti-inflammatory drug to inhibit bone progression in spondyloarthritis
Jin Sun Choi, Ji-Young Kim, Min-joo Ahn, Seungtaek Song, Doyoun Kim, Sung Hoon Choi, Ye-Soo Park, Tae-Jong Kim, Sungsin Jo, Tae-Hwan Kim, Seung Cheol Shim
BMB Reports.2025; 58(3): 140. CrossRef
Non-celiac Enteropathies
Kaitlyn Mi, Scarlett Cao, Dawn Adams
Current Gastroenterology Reports.2025;[Epub] CrossRef
Integrated approach to reducing polypharmacy in older people: exploring the role of oxidative stress and antioxidant potential therapy
Catalina Rojas-Solé, Víctor Pinilla-González, José Lillo-Moya, Tommy González-Fernández, Luciano Saso, Ramón Rodrigo
Redox Report.2024;[Epub] CrossRef
Non-steroidal anti-inflammatory drug induced intestinal stricturing: diaphragm disease
Nathan Johnson, Maseera Solkar, Rishabh Sehgal, Kallingal Riyad
Journal of Surgical Case Reports.2024;[Epub] CrossRef
Jejunal Diverticulosis: An Atypical Lead Point for Small Bowel Volvulus
Divij Agarwal, Iqbal Ali, Varun Shetty
Cureus.2024;[Epub] CrossRef
Predictors of elevated C-reactive protein among pre-treatment, newly diagnosed breast cancer patients: A cross-sectional study
Wai Han Ng, Zalina Abu Zaid, Barakatun Nisak Mohd Yusof, Syafinaz Amin Nordin, Poh Ying Lim
Cancer Treatment and Research Communications.2024; 39: 100813. CrossRef
Diagnosis of Small Intestinal Diaphragms and Strictures Induced by Non-steroidal Anti-inflammatory Drugs Through Intraoperative Enteroscopy: A Case Study From Saudi Arabia
Rafaat M Chakik, Nasser I Alqahtani, Yahia Al-Hagawi, Saeed Nasser Alsharif, Abdullah S Alqahtani, Dawlah Hadi Asiri, Salihah Y Al-Mani
Cureus.2024;[Epub] CrossRef
DA-9601 has protective effects comparable to those of proton pump inhibitor and rebamipide against nonsteroidal anti-inflammatory drugs-induced upper and lower gastrointestinal bleeding in patients with rheumatoid arthritis: A nationwide study using Korea
Min Wook So, Aran Kim, Seung-Geun Lee
Medicine.2024; 103(27): e38801. CrossRef
NSAID-Induced Lower Gastrointestinal Bleeding: A Case Report
Mahmoud Nafie, Weeraput Chadbunchachai, Christo Lapa, Stephen Gregory, Joseph William Nunoo-Mensah
World Journal of Colorectal Surgery.2024; 13(2): 49. CrossRef
Drugs Effective for Nonsteroidal Anti-inflammatory Drugs or Aspirin-induced Small Bowel Injuries
Younghee Choe, Jae Myung Park, Joon Sung Kim, Yu Kyung Cho, Byung-Wook Kim, Myung-Gyu Choi, Na Jin Kim
Journal of Clinical Gastroenterology.2024; 58(10): 1003. CrossRef
Massive Gastrointestinal Bleeding Related to NSAID Use in a Patient with Ileorectal Anastomosis
Esere Nesiama, Letisha Mirembe, Kierra Weber, Sruthy Isaac, Deborah Trammell, Izi Obokhare, Andee Dzulkarnaen Zakaria
Case Reports in Surgery.2024;[Epub] CrossRef
Rebamipide Prevents the Hemoglobin Drop Related to Mucosal-Damaging Agents at a Level Comparable to Proton Pump Inhibitors
Ji Eun Kim, Yeong Chan Lee, Tae Se Kim, Eun Ran Kim, Sung Noh Hong, Young-Ho Kim, Kyunga Kim, Dong Kyung Chang
Gut and Liver.2024; 18(6): 1026. CrossRef
Effect of tegoprazan, a novel potassium-competitive acid blocker, on non-steroidal anti-inflammatory drug (NSAID)-induced enteropathy
Hyun Jung Lee, Ji Wook Moon, Seong-Joon Koh, Jong Pil Im, Byeong Gwan Kim, Joo Sung Kim
Scientific Reports.2024;[Epub] CrossRef
Automedicação e úlcera péptica induzida por AINEs
Maria Luiza Almeida Sena, Thalita Novais Reis, Mateus Brancutti Farina Mafessoni, Emily Moraes Libardi, Sarah Fernandes Teixeira
Cuadernos de Educación y Desarrollo.2024; 16(12 Edição ): e6495. CrossRef
Diaphragmatic small bowel disease in a patient with resistant migraine and medication overuse treated with galcanezumab
Marilena Marcosano, Nicoletta Brunelli, Alessandro Alesina, Luisa Fofi, Claudia Altamura, Fabrizio Vernieri
Confinia Cephalalgica.2024;[Epub] CrossRef
A Practical Index to Distinguish Backwash Ileitis From Crohn’s Terminal Ileitis in MR Enterography
Bardia Khosravi, Aneseh Salehnia, Neda Pak, S Ali Montazeri, Ali Reza Sima, Homayoun Vahedi, Reza Malekzadeh, Amir Reza Radmard
Inflammatory Bowel Diseases.2023; 29(1): 42. CrossRef
Toxic effects of naproxen on the intestine of the goldfish, Carassius auratus
Jing Wang, Weijing Kong, Qianhang Sun, Xin Zheng, Shuping Wang, Zhenguang Yan
Molecular & Cellular Toxicology.2023; 19(4): 667. CrossRef
Non-steroidal anti-inflammatory drugs (NSAIDs): A current insight into its molecular mechanism eliciting organ toxicities
Nagesh Kishan Panchal, Evan Prince Sabina
Food and Chemical Toxicology.2023; 172: 113598. CrossRef
Extract of Laurus nobilis attenuates inflammation and epithelial ulcerations in an experimental model of inflammatory bowel disease
Natalie Correa, Robert Orlando
WikiJournal of Medicine.2023; 10(1): 2. CrossRef
Nonsteroidal Anti-Inflammatory Drug-Induced Jejunal Ulcer Identified by Capsule Endoscopy
Salman B. Syed, Ishaan Vohra, Sonu Dhillon, Omar S. Khokhar
ACG Case Reports Journal.2023; 10(3): e00969. CrossRef
AINE, toxicidad gastrointestinal y enfermedad inflamatoria intestinal
Gonzalo Hijos-Mallada, Carlos Sostres, Fernando Gomollón
Gastroenterología y Hepatología.2022; 45(3): 215. CrossRef
Gastrointestinal and cardiovascular adverse events associated with NSAIDs
María-José Domper Arnal, Gonzalo Hijos-Mallada, Angel Lanas
Expert Opinion on Drug Safety.2022; 21(3): 373. CrossRef
Protection against indomethacin-induced loss of intestinal epithelial barrier function by a quercetin oxidation metabolite present in onion peel: In vitro and in vivo studies
Jocelyn Fuentes, Oscar Brunser, Elías Atala, José Herranz, Adriano Costa de Camargo, Hermann Zbinden-Foncea, Hernán Speisky
The Journal of Nutritional Biochemistry.2022; 100: 108886. CrossRef
Reducing Pain in Experimental Models of Intestinal Inflammation Affects the Immune Response
Laura Golusda, Anja A Kühl, Britta Siegmund, Daniela Paclik
Inflammatory Bowel Diseases.2022; 28(5): 801. CrossRef
Revisiting the Oxidation of Flavonoids: Loss, Conservation or Enhancement of Their Antioxidant Properties
Hernan Speisky, Fereidoon Shahidi, Adriano Costa de Camargo, Jocelyn Fuentes
Antioxidants.2022; 11(1): 133. CrossRef
Comprehensive Evaluation and Unique Morphologic Features of Nonsteroidal Anti-Inflammatory Drug (NSAID) Enteropathy in the Terminal Ileum
Jessica Nguyen, Sherry Lee, Guang-Yu Yang
International Journal of Surgical Pathology.2022; 30(6): 616. CrossRef
NSAIDs, gastrointestinal toxicity and inflammatory bowel disease
Gonzalo Hijos-Mallada, Carlos Sostres, Fernando Gomollón
Gastroenterología y Hepatología (English Edition).2022; 45(3): 215. CrossRef
Effect of the combination of mexidol and diclofenac sodium on exudative inflammation in rats after ten-day preventive oral administration
E. A. Ivanova, A. G. Vasilchuk, A. I. Matyushkin, T. A. Voronina
Pharmacokinetics and Pharmacodynamics.2022; (1): 14. CrossRef
The role of Zinc L-Carnosine in the prevention and treatment of gastrointestinal mucosal disease in humans: a review.
Konstantinos Efthymakis, Matteo Neri
Clinics and Research in Hepatology and Gastroenterology.2022; 46(7): 101954. CrossRef
Therapeutic Versus Preventative Use of Ginkgo biloba Extract (EGb 761) against Indomethacin-Induced Gastric Ulcer in Mice
Ahmed M. Abd-Eldayem, Sulaiman Mohammed Alnasser, Hanan H. Abd-Elhafeez, Soha A. Soliman, Rania A. Abdel-Emam
Molecules.2022; 27(17): 5598. CrossRef
Effects of Canine-Obtained Lactic-Acid Bacteria on the Fecal Microbiota and Inflammatory Markers in Dogs Receiving Non-Steroidal Anti-Inflammatory Treatment
Kristin M. V. Herstad, Hilde Vinje, Ellen Skancke, Terese Næverdal, Francisca Corral, Ann-Katrin Llarena, Romy M. Heilmann, Jan S. Suchodolski, Joerg M. Steiner, Nicole Frost Nyquist
Animals.2022; 12(19): 2519. CrossRef
The Different Patterns of Over-the-Counter Nonsteroidal Anti-Inflammatory Drugs or Analgesics Use in Patients with Chronic Kidney Disease and the General Population
Maria Mulka-Gierek, Natalia Krata, Bartosz Foroncewicz, Leszek Pączek, Krzysztof Mucha
Healthcare.2022; 10(10): 2035. CrossRef
Manifestaciones gastrointestinales de la enfermedad de Behçet
Nicolás Zuluaga Arbeláez, Oscar Mauricio Ardila Suarez, Andrés Chavarriaga Restrepo, Wilmer Gerardo Rojas-Zuleta
CES Medicina.2022; 36(3): 86. CrossRef
Iron Deficiency Anaemia and Anaemia of Inflammation in Enteropathies Caused by Commonest Small Intestine Disorders: Current Evidence
Olesja Basina, Jelena Derova, Aleksejs Derovs, Sandra Lejniece
Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences..2022; 76(5-6): 561. CrossRef
Prominent Indomethacin-Induced Enteropathy in Fcgriib Defi-cient lupus Mice: An Impact of Macrophage Responses and Immune Deposition in Gut
Thansita Bhunyakarnjanarat, Kanyarat Udompornpitak, Wilasinee Saisorn, Bhumdhanin Chantraprapawat, Peerapat Visitchanakun, Cong Phi Dang, Jiraphorn Issara-Amphorn, Asada Leelahavanichkul
International Journal of Molecular Sciences.2021; 22(3): 1377. CrossRef
Quercetin Oxidation Metabolite Present in Onion Peel Protects Caco-2 Cells against the Oxidative Stress, NF-kB Activation, and Loss of Epithelial Barrier Function Induced by NSAIDs
Jocelyn Fuentes, Adriano Costa de Camargo, Elías Atala, Martín Gotteland, Claudio Olea-Azar, Hernán Speisky
Journal of Agricultural and Food Chemistry.2021; 69(7): 2157. CrossRef
Clinical Course of Terminal Ileal Ulcers Observed Incidentally During Colonoscopy
Jae Hyun Kim, Jong Yoon Lee, Yong Eun Park, Jong Hoon Lee, Jongha Park, Tae Oh Kim, Won Moon, Seun Ja Park
Digestive Diseases and Sciences.2021; 66(12): 4423. CrossRef
Synergistic Action of Diclofenac with Endotoxin-Mediated Inflammation Exacerbates Intestinal Injury in Vitro
Wen Li Kelly Chen, Emily Suter, Hikaru Miyazaki, Jason Velazquez, Douglas A. Lauffenburger, Linda G. Griffith, Rebecca L. Carrier
ACS Infectious Diseases.2021; 7(4): 838. CrossRef
Pure Total Flavonoids From Citrus Protect Against Nonsteroidal Anti-inflammatory Drug-Induced Small Intestine Injury by Promoting Autophagy in vivo and in vitro
Shanshan Chen, Jianping Jiang, Guanqun Chao, Xiaojie Hong, Haijun Cao, Shuo Zhang
Frontiers in Pharmacology.2021;[Epub] CrossRef
MODULATION OF MELOXICAM-INDUCED CHANGES IN GASTROINTESTINAL AND MOTOR ACTIVITY OF THE STOMACH BY APPLYING PLACENTA CRYOEXTRACT
Fedir Hladkykh, Mykola Chyzh
Proceedings of the Shevchenko Scientific Society. Medical Sciences.2021;[Epub] CrossRef
Phytochemical Investigation and HPTLC Fingerprinting Analysis ofSelaginella bryopterisEthanolic Plant Extract for Analgesic and Anti-inflammatory Activities in Animals
Shravan Kumar Paswan, Pritt Verma, Lubna Azmi, Sajal Srivastava, Chandana Venkateswara Rao
Journal of Biologically Active Products from Nature.2021; 11(4): 395. CrossRef
RETRACTED ARTICLE: Expansion of monocytic myeloid-derived suppressor cells ameliorated intestinal inflammatory response by radiation through SOCS3 expression
You Yeon Choi, Ki Moon Seong, Hyun Jung Lee, Seung Sook Lee, Areumnuri Kim
Cell Death & Disease.2021;[Epub] CrossRef
Synthesis and Biological Evaluation of Salicylic Acid Analogues of Celecoxib as a New Class of Selective Cyclooxygenase-1 Inhibitor
Sung-Hwa Yoon, Duk-Yeon Cho, Seoung-ryoung Choi, Joo-young Lee, Dong-Kug Choi, Eunha Kim, Ju-Young Park
Biological and Pharmaceutical Bulletin.2021; 44(9): 1230. CrossRef
Mucoprotective drugs can prevent and treat nonsteroidal anti-inflammatory drug-induced small bowel enteropathy: a systematic review and meta-analysis of randomized controlled trials
Brigitta Teutsch, Eszter Boros, Szilárd Váncsa, Alex Váradi, Levente Frim, Szabolcs Kiss, Fanni Dembrovszky, Zsuzsanna Helyes, Sarlós Patrícia, Hegyi Péter, Bálint Erőss
Therapeutic Advances in Gastroenterology.2021;[Epub] CrossRef
Predictors of Positive Video Capsule Endoscopy Findings for Chronic Unexplained Abdominal Pain: Single-Center Retrospective Study and Meta-Analysis
Wonshik Kim, Beomjae Lee, Ahyoung Yoo, Seunghan Kim, Moonkyung Joo, Jong-Jae Park
Diagnostics.2021; 11(11): 2123. CrossRef
NSAID-Induced Enteropathy Affects Regulation of Hepatic Glucose Production by Decreasing GLP-1 Secretion
Hussein Herz, Yang Song, Yuanchao Ye, Liping Tian, Benjamin Linden, Marwa Abu El Haija, Yi Chu, Justin L. Grobe, Randall W. Lengeling, Mohamad Mokadem
Nutrients.2021; 14(1): 120. CrossRef
Anti-Inflammatory Properties of Diclofenac Sodium on Background of Its Combined Use With Cryopreserved Placenta Extract in Experiment
Fedir Hladkykh
Problems of Cryobiology and Cryomedicine.2021; 31(4): 364. CrossRef
Utility of intestinal ultrasound in the diagnosis and short-term follow-up of non-steroidal anti-inflammatory drug-induced enteropathy
Matteo Pistoia, Tiziano Perrone, Anna Fiengo, Marco Vincenzo Lenti, Antonio Di Sabatino
Internal and Emergency Medicine.2020; 15(4): 729. CrossRef
Consenso mexicano sobre diagnóstico, prevención y tratamiento de la gastropatía y enteropatía por antiinflamatorios no esteroideos
M.V. Bielsa-Fernández, J.L. Tamayo-de la Cuesta, J. Lizárraga-López, J.M. Remes-Troche, R. Carmona-Sánchez, J.M. Aldana-Ledesma, J.M. Avendaño-Reyes, M.A. Ballesteros-Amozorrutia, M. De Ariño, L. de Giau-Triulzi, R. Flores-Rendón, H. Huerta-Guerrero, J.A.
Revista de Gastroenterología de México.2020; 85(2): 190. CrossRef
The Mexican consensus on the diagnosis, treatment, and prevention of NSAID-induced gastropathy and enteropathy
M.V. Bielsa-Fernández, J.L. Tamayo-de la Cuesta, J. Lizárraga-López, J.M. Remes-Troche, R. Carmona-Sánchez, J.M. Aldana-Ledesma, J.M. Avendaño-Reyes, M.A. Ballesteros-Amozorrutia, M. De Ariño, L. de Giau-Triulzi, R. Flores-Rendón, H. Huerta-Guerrero, J.A.
Revista de Gastroenterología de México (English Edition).2020; 85(2): 190. CrossRef
Impact of host and environmental factors on β-glucuronidase enzymatic activity: implications for gastrointestinal serotonin
Jacinta Walsh, Loreto Olavarria-Ramirez, Gilliard Lach, Marcus Boehme, Timothy G. Dinan, John F. Cryan, Brendan T. Griffin, Niall P. Hyland, Gerard Clarke
American Journal of Physiology-Gastrointestinal and Liver Physiology.2020; 318(4): G816. CrossRef
Glycomacropeptide Ameliorates Indomethacin-Induced Enteropathy in Rats by Modifying Intestinal Inflammation and Oxidative Stress
Daniel Cervantes-García, Armida I. Bahena-Delgado, Mariela Jiménez, Laura E. Córdova-Dávalos, Vanessa Ruiz-Esparza Palacios, Esperanza Sánchez-Alemán, María C. Martínez-Saldaña, Eva Salinas
Molecules.2020; 25(10): 2351. CrossRef
Non-steroidal anti-inflammatory drug-induced enteropathy as a major risk factor for small bowel bleeding: a retrospective study
Doo-Ho Lim, Kyoungwon Jung, Seung Bum Lee, In Kyu Park, Hee Jeong Cha, Jae Ho Park, Byung Gyu Kim, Seok Won Jung, In Du Jeong, Jae Hyun Kim, Sung Eun Kim, Won Moon, Moo In Park, Seun Ja Park
BMC Gastroenterology.2020;[Epub] CrossRef
Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective
Samik Bindu, Somnath Mazumder, Uday Bandyopadhyay
Biochemical Pharmacology.2020; 180: 114147. CrossRef
NSAID–Gut Microbiota Interactions
Damian Maseda, Emanuela Ricciotti
Frontiers in Pharmacology.2020;[Epub] CrossRef
Minimal Lesions of the Small Intestinal Mucosa: More than Morphology
Umberto Volta, Giacomo Caio, Caterina Ghirardi, Lisa Lungaro, Pasquale Mansueto, Antonio Carroccio, Roberto De Giorgio
Digestive Diseases and Sciences.2020; 65(10): 2761. CrossRef
The Protective Effect of Lercanidipine on Indomethacin-Induced Gastric Ulcers in Rats
Durdu Altuner, Tuğba Kaya, Halis Suleyman
Brazilian Archives of Biology and Technology.2020;[Epub] CrossRef
Investigation of small intestinal lesions in dialysis patients using capsule endoscopy
Fumitaka Nakajima, Yoshiyuki Furumatsu, Takatomi Yurugi, Yoshifumi Amari, Takeshi Iida, Takayuki Fukui, Takanori Kuramoto
Hemodialysis International.2019; 23(1): 77. CrossRef
Gastroprotective effect of memantine in indomethacin-induced peptic ulcer in rats, a possible role for potassium channels
Remon R. Rofaeil, Shereen S. Gaber
Life Sciences.2019; 217: 164. CrossRef
Proton pump inhibitor use is associated with elevated faecal calprotectin levels. A cross-sectional study on subjects referred for colonoscopy
David Lundgren, Vincy Eklöf, Richard Palmqvist, Johan Hultdin, Pontus Karling
Scandinavian Journal of Gastroenterology.2019; 54(2): 152. CrossRef
Effects of Misoprostol for Aspirin-induced Small Bowel Enteropathy
Dong Han Yeom, Han Seung Ryu
The Korean Journal of Gastroenterology.2019; 73(1): 60. CrossRef
Effects of Drugs and Excipients on Hydration Status
Ana M. Puga, Sara Lopez-Oliva, Carmen Trives, Teresa Partearroyo, Gregorio Varela-Moreiras
Nutrients.2019; 11(3): 669. CrossRef
Small bowel ulcers
Martin Keuchel, Niehls Kurniawan, Peter Baltes
Current Opinion in Gastroenterology.2019; 35(3): 213. CrossRef
Cardiorespiratory fitness, visceral fat, and body fat, but not dietary inflammatory index, are related to C-reactive protein in cancer survivors
Matthew A Christensen, Peter Smoak, Jonathon K Lisano, Reid Hayward, Craig Coronado, Katie Kage, Daniel Shackelford, Laura K Stewart
Nutrition and Health.2019; 25(3): 195. CrossRef
Safety and tolerability of nsaids: focus on aceclofenac
E. A. Ushkalova, S. K. Zyryanov, K. E. Zalolochina
Medical Council.2019; (9): 110. CrossRef
NSAIDs disrupt intestinal homeostasis by suppressing macroautophagy in intestinal epithelial cells
Ana M. Chamoun-Emanuelli, Laura K. Bryan, Noah D. Cohen, Taylor L. Tetrault, Joseph A. Szule, Rola Barhoumi, Canaan M. Whitfield-Cargile
Scientific Reports.2019;[Epub] CrossRef
Reproduction of inflammatory bowel diseases in experiment
A. TRUSHENKO, V. MAMCHUR
Experimental and Clinical Physiology and Biochemistry.2019; 2019(3): 82. CrossRef
A Case Report on Functional Dyspepsia in a Fibromyalgia Patient with a History of Long-Term Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Use
Keum-ji Kim, Soo-ho Cho, Ji-seon Park, Seok-jae Ko, Jae-woo Park
The Journal of Internal Korean Medicine.2019; 40(6): 1268. CrossRef
Are NSAIDs Double Trouble?
Sam Schulman, James Aisenberg
Journal of the American College of Cardiology.2018; 72(3): 268. CrossRef
Microbiota–drug interactions: Impact on metabolism and efficacy of therapeutics
Ellen M. Wilkinson, Zehra Esra Ilhan, Melissa M. Herbst-Kralovetz
Maturitas.2018; 112: 53. CrossRef
Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells
Chenke Xu, Wei Wang, Jin Zhong, Fan Lei, Naihan Xu, Yaou Zhang, Weidong Xie
Biochemical Pharmacology.2018; 152: 45. CrossRef
Misoprostol for NSAID-induced small bowel erosions and ulcers
Timothy A Rockall
The Lancet Gastroenterology & Hepatology.2018; 3(7): 447. CrossRef
Rebleeding rate and risk factors in nonsteroidal anti‐inflammatory drug‐induced enteropathy
Junseok Park, Seong Ran Jeon, Jin‐Oh Kim, Hyun Gun Kim, Tae Hee Lee, Jun‐Hyung Cho, Bong Min Ko, Joon Seong Lee, Moon Sung Lee
Journal of Digestive Diseases.2018; 19(5): 279. CrossRef
Nonsteroidal anti-inflammatory drugs use and risk of Parkinson disease
Li Ren, Jie Yi, Jing Yang, Peng Li, Xueyan Cheng, Peixian Mao
Medicine.2018; 97(37): e12172. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Non-steroidal anti-inflammatory drug-induced enteropathy

Intest Res. 2017;15(4):446-455. Published online October 23, 2017

DOI: https://doi.org/10.5217/ir.2017.15.4.446

XML Download

Figure

Non-steroidal anti-inflammatory drug-induced enteropathy

Fig. 1 Putative pathophysiology of NSAID-induced enteropathy. NSAIDs decrease PG synthesis, resulting in the reduction of mucus and blood flow of the intestinal mucosa and directly damage the small bowel epithelium. These injuries cause increased intestinal permeability of bile acid, bacteria, proteolytic enzymes, and toxins. Therefore, neutrophils and many inflammatory mediators are activated and various clinical manifestations, such as erosion, ulceration, bleeding, and protein loss develop. Additionally, enterohepatic circulation of NSAIDs and bile augments the damage to the small bowel. TLR4, Toll-like receptor 4. Adapted from Wallace JL. Br J Pharmacol 2012;165:67-74.18

Fig. 2 Capsule endoscopic images of various intestinal mucosal lesions by NSAID. (A) Small bowel petechiae, (B) small bowel erosion, (C) small bowel ulcer, (D) small bowel ulcer with adherent blood clots, (E) small bowel active bleeding, and (F) small bowel stricture with adherent clots.

Fig. 1

Fig. 2

Non-steroidal anti-inflammatory drug-induced enteropathy